As biological data volume continues to grow, sequence-based AI is poised to become the dominant discovery layer across pharma ...

Interdisciplinary work in the life sciences at the boundaries of biology, chemistry and physics is making enormous strides. This progress was showcased at the recent Single Molecule Biophysics ...

NVIDIA and Lilly to invest $1B in AI lab to accelerate drug discovery with BioNeMo, robotics, and large-scale biomedical ...

Quantum physics is no longer confined to cryogenic chips and vacuum chambers. It is starting to seep into the machinery of ...

NVIDIA and Lilly put $1B behind AI as core drug infrastructure During the JPMorgan Healthcare Conference week in mid January ...

“The cleverer I am about miniaturizing the world, the better I am at possessing it.” That line of thinking, as practiced in nanoscale engineering, has no stronger embodiment today than ChemLex’s newly ...

New “AI GYM for Science” dramatically boosts the biological and chemical intelligence of any causal or frontier LLM, ...

Outside the JPM Healthcare Conference, Thomas Clozel, cofounder and CEO of Owkin, sat down with MobiHealthNews to discuss how ...

Inside the race to turn one of cell biology’s least understood processes into a new foundation for drug development and ...

The company applies AI to optimize molecules across discovery and production with aims to contribute to the rebuilding of U.S.-based drug innovation and manufacturing.

The partnership brings together Pfizer’s scientific data and therapeutic expertise with Boltz’s open-source AI foundation models.

We combined protein engineering and single molecule measurements to directly record the step size of a series of myosin constructs with shortened and elongated artificial neck domains. Our results ...